1. Home
  2. LTBR vs ACOG Comparison

LTBR vs ACOG Comparison

Compare LTBR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$5.08

Market Cap

198.7M

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.29

Market Cap

193.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTBR
ACOG
Founded
1992
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
198.7M
193.6M
IPO Year
2015
2024

Fundamental Metrics

Financial Performance
Metric
LTBR
ACOG
Price
$5.08
$8.29
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $18.00
AVG Volume (30 Days)
★ 640.8K
88.2K
Earning Date
11-02-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 41.58
EPS
★ N/A
N/A
Revenue
N/A
★ $10,220,275.00
Revenue This Year
N/A
$153.87
Revenue Next Year
N/A
$85.66
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.87
$4.50
52 Week High
$28.44
$10.14

Technical Indicators

Market Signals
Indicator
LTBR
ACOG
Relative Strength Index (RSI) 33.45 41.03
Support Level $4.87 $8.30
Resistance Level $7.04 $9.48
Average True Range (ATR) 0.34 0.43
MACD -0.03 -0.05
Stochastic Oscillator 8.75 21.29

Price Performance

Historical Comparison
LTBR
ACOG

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, engaged in research and development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: